Introduction {#sec1-1}
============

Ischemic stroke, dementia, Alzheimer's disease and other ischemic cerebrovascular diseases are common entities that share a similar pathophysiology. Thrombolytic therapy is the common treatment for early ischemic cerebrovascular disease and can effectively restore the blood supply to the ischemic area. However, cerebral ischemia/reperfusion injury during thrombolytic therapy might lead to a series of pathological reactions including oxidative stress, calcium overload, glutamate excitotoxicity, inflammation, and apoptosis (Gong et al., 2014; Girbovan and Plamondon, 2015). Increasingly, studies have demonstrated that autophagy, or cellular self-digestion, is also involved in the neurological damage and cell death induced by cerebral ischemia/reperfusion injury (Li et al., 2016; Wang and An, 2016). More specifically, although autophagy plays a protective role in the early reperfusion period through cleaning damaged organelles and proteins (Su et al., 2014), during the late reperfusion period, excessive autophagy causes autophagic cell death, leading to subsequent damage of cells and tissues (Guo et al., 2014; Shui et al., 2016). Therefore, preventing and reversing cerebral ischemia/reperfusion injury through autophagy modulation is a potential novel therapeutic goal.

Electroacupuncture (EA) serves as a complementary and alternative therapy for prevention and rehabilitation of ischemic cerebrovascular disease. It has been found to be potentially beneficial for reducing cerebral ischemia/reperfusion injury *via* benign regulation of oxidative stress (Lin et al., 2015), glutamate excitotoxicity (Sun et al., 2005), inflammation (Zhan et al., 2016), apoptosis (Liu et al., 2015; Zhang et al., 2018), and autophagy (Feng et al., 2018; Li et al., 2018). Indeed, studies (He et al., 2015; Li et al., 2016; Liu et al., 2016a; Shu et al., 2016) have shown that EA plays a key role in the whole process of autophagy, which includes the initiation of autophagy, vesicle nucleation, expansion and maturation of autophagosomes, and fusion and degradation of autophagolysosomes. Furthermore, studies (He et al., 2015; Wu et al., 2015) have indicated that the benefits could result from regulation of the mammalian target of rapamycin (mTOR)-related signaling pathway. It was reported that different EA parameters such as the selected acupoints as well as the current intensity, waveform, and duration of stimulation, produced different effects against cerebral ischemia/reperfusion injury (Shu et al., 2016; Feng et al., 2018). This article aims to provide a therapeutic target based on autophagy for EA treatment against ischemic cerebrovascular diseases.

Relevant studies were retrieved from online electronic databases including, PubMed, Embase, Web of Science, and China National Knowledge Infrastructure. Search terms consisted of three groups: autophagy, interventions (acupuncture, electroacupuncture, and EA), and diseases (ischemic stroke, cerebral ischemia, and cerebral ischemia reperfusion injury). All the articles in this review were published by August 2018 and were available in full text.

Process and Molecular Mechanism of Autophagy {#sec1-2}
============================================

Autophagy is an evolutionarily conserved self-degradative process that involves the break down and recycling of long-lived proteins, lipids, and organelles, and is essential for cellular homeostasis and survival (Parzych and Klionsky, 2014; Lu et al., 2018). Generally, there are three types of autophagy: macroautophagy, microautophagy, and chaperone mediated autophagy (Glick et al., 2010), among which, macroautophagy is most widely studied in relation to cerebral ischemia/reperfusion injury. The progress of macroautophagy (hereafter called autophagy) has several stages, including initiation, vesicle nucleation, expansion and maturation of autophagosomes, and fusion and degradation of autophagolysosomes (Hale et al., 2013; Chen et al., 2014; Huang et al., 2015b). The whole process is defined as autophagic flux (Lu and Hu, 2016) and involves a series of molecules (**[Figure 1](#F1){ref-type="fig"}**).

![Process and molecular mechanisms of autophagy in cerebral ischemia/reperfusion injury (CIRI).\
The process of macroautophagy goes through initiation, vesicle nucleation, expansion and maturation of autophagosomes, and fusion and degradation of autophagolysosomes. Cerebral ischemia/reperfusion leads to a lower level of ATP and activates AMPK, which further inhibits mTORC1 and activates the ULK1-Atg 13-focal adhesion kinase FIP200 complex, thus initiating autophagy. The ULK1-Atg13-FIP200 complex phosphorylates Beclin-1 and activates the class-III PI3K complex, promoting the formation of vesicles with double-layer membranes. The double-membrane further bends and extends to form mature autophagosomes, a process that requires the Atg12-Atg5-Atg16L1 complex and the LC3-PE conjugate. The fusion of autophagosomes and lysosomes is mediated by SNAREs, small GTPase Rab7, and other proteins. Finally, the autophagolysosomes are degraded by lysosomal enzymes, which requires p62-mediated degradation of cargoes. ATP: Adenosine triphosphate; AMPK: adenosine monophosphate-activated protein kinase; mTORC1: mammalian target of rapamycin complex 1; ULK1: UNC-51-like kinase-1; Atg: autophagy-related-gene; FIP200: family-interacting protein of 200 kDa; PI3K: phosphatidylinositol 3-kinase; LC3: microtubule associated protein-1 light chain 3; PE: phosphatidylethanolamine; UVRAG: UV radiation resistance-associated gene; SNARE: soluble N-ethylmaleimide sensitive factor attachment protein receptors.](NRR-14-954-g001){#F1}

Autophagy can be induced by ischemia, hypoxia, and stress responses during cerebral ischemia/reperfusion injury (Wang et al., 2018). In most cases, the initiation of autophagy is modulated by mammalian target of rapamycin complex 1 (mTORC1) (Rabanal-Ruiz et al., 2017). Additionally, the ULK1 complex---consisting of UNC-51-like kinase-1 (ULK1) or ULK2, focal adhesion kinase family-interacting protein of 200 kDa (FIP200), and autophagy-related-gene (Atg) 13---also plays a key role at this stage (Ganley et al., 2009). Under nutrient-rich conditions, mTORC1 inhibits the initiation of autophagy by activating the ULK1 complex and phosphorylating ULK1 and Atg13. Under nutrient-deficient conditions, mTORC1 dissociates from the ULK1 complex to induce autophagy (Rabanal-Ruiz et al., 2017).

Following initiation, a double-membrane vesicle is formed around the organelles and proteins that are to be degraded. At this stage, the class-III phosphatidylinositol 3-kinase (PI3K) complex---consisting of PI3K (mammalian homolog of yeast Vps34), Beclin1 (a homolog of Atg6), and p150 (a homolog of Vps15)---plays an essential role. Moreover, Atg1 and Atg9 are also required for vesicle nucleation (Sun et al., 2009). Further bending and extending of the double-membrane help the formation of mature autophagosomes, and the item to be degraded is wrapped in the double-membrane. At this stage, two ubiquitin-like conjugating systems, namely, the Atg12-Atg5-Atg16-like 1 (Atg16L1) complex (Kim et al., 2015; Chandra et al., 2016) and microtubule-associated protein-1 light-chain 3 (LC3) (a homolog of Atg8) phosphatidylethanolamine conjugate are required (Satoo et al., 2009; Yang et al., 2017).

The fusion of matured autophagosomes and lysosomes facilitates the formation of autophagolysosomes through acidification. After which, the encapsulated mitochondria, endoplasmic reticulum, or other organelles or proteins in the autophagolysosomes are degraded by lysosomal enzymes, and the degraded product is released into the cells for recycling. SNAREs, small GTPase Rab7, and lysosome-associated membrane protein (LAMP)-1 and LAMP-2 are required for the fusion (Hubert et al., 2016). The autophagosome membrane-protein p62 and the degradation of cargoes sequestered by autophagolysosomes are involved in the final step (Katsuragi et al., 2015; Liu et al., 2016b).

Role of Autophagy in Cerebral Ischemia/Reperfusion Injury {#sec1-3}
=========================================================

Previous studies have demonstrated that a series of complicated pathological processes, including oxidative stress (Rodrigo et al., 2013), endoplasmic reticulum stress (Xin et al., 2014), excitotoxicity (Hou and MacManus, 2002), calcium overload (Halestrap, 2006), inflammatory response (Ahmad et al., 2014), apoptosis (Lopez-Neblina et al., 2005), and autophagy (Xu and Zhang, 2011) are involved in the mechanisms underlying cerebral ischemia/reperfusion injury. Research based on autophagy has revealed a complex relationship between autophagy and other pathological changes; autophagy can be elicited by oxidative stress (Filomeni et al., 2015), endoplasmic reticulum stress (Meng et al., 2015), and excitotoxicity (Puyal et al., 2012), and these pathological changes can be secondarily reversed by activated autophagy.

However, the role of autophagy in cerebral ischemia/reperfusion injury remains controversial. Studies have suggested that autophagy can be a double-edged sword in terms of its role in cerebral ischemia/reperfusion injury (Wei et al., 2012; Chen et al., 2014). During the first few hours of reperfusion, autophagy plays a protective role in cerebral ischemia/reperfusion injury by degrading damaged organelles and misfolded proteins, and by producing amino acids and nucleotides for recycling (Yan et al., 2011; Xia et al., 2013). However, if still active in the later stages of reperfusion, autophagy can lead to over-degradation of undamaged organelles and proteins, finally leading to autophagic cell death and secondary damage to cells and tissues (Gao et al., 2012; Wu et al., 2015). Therefore, autophagy regulation is thought to be a potential therapy target for cerebral ischemia/reperfusion injury. Recent studies have indicated that some traditional Chinese medicines, particularly acupuncture, might act against cerebral ischemia/reperfusion injury by modulating autophagy (Yang et al., 2016; Ting et al., 2017; Huang et al., 2018). Indeed, this has become a hot topic in the research community.

Electroacupuncture for Cerebral Ischemia/Reperfusion Injury *via* Modulating Autophagy {#sec1-4}
======================================================================================

Acupuncture, one of the most important components of traditional Chinese medicine, has been used to prevent and rehabilitate diseases for more than 3000 years (Zhuang et al., 2013; Yu et al., 2018). With its remarkable effects as an adjuvant therapy, acupuncture now has been generally acknowledged worldwide as an alternative medicine. As early as 1979, acupuncture needles were approved by the U.S. Food and Drug Administration as a Class III (investigational) medical device and their clinical application was approved for licensed practitioners (Hammerschlag, 2000). In the same year, the World Health Organization approved 43 kinds of diseases and disorders such as nausea and vomiting, pain, and the rehabilitation of ischemic stroke as treatable with acupuncture. Moreover, evidence from laboratories indicated that EA, a clinical therapy combining electrical stimulation and needle insertion, could dramatically restore blood supply, reduce the volume of cerebral infarct, ameliorate learning and memory impairment, and reduce neurological deficits in rats with cerebral ischemia/reperfusion injury (Feng et al., 2018; Li et al., 2018). The beneficial efficacy was considered to be achieved through modulation of autophagy-related markers.

Electroacupuncture modulates the initiation of autophagy {#sec2-1}
--------------------------------------------------------

AMP-activated protein kinase (AMPK)---an intracellular energy sensor---is activated by a rise in the AMP/ATP ratio that occurs following the fall in ATP levels during cerebral ischemia/reperfusion injury (Manwani and McCullough, 2013). Further, AMPK inhibits the activation of mTOR through phosphorylating TSC2, which is a negative regulatory protein of mTOR. Inactivated mTOR rapidly dephosphorylates Atg13 and ULK1, leading to the formation of the ULK1 complex and eventually accelerating the initiation of autophagy (Alers et al., 2012; Gallagher et al., 2016).

In one study, EA (dense disperse wave; frequency, 1--20 Hz; peak voltage, 6 V; intensity, 0.2 mA) was applied to the *Quchi* (LI11) and *Zusanli* (ST36) acupoints 30 min/day for 3 days, starting 24 hours after reperfusion in a Sprague-Dawley rat middle cerebral artery-occlusion model. The result was a significant reduction of neurological deficits and cerebral infarct volume, significantly down-regulated protein expression levels for ULK1 and Atg13, and up-regulated protein expression levels for mTORC1. Thus, it effectively protected the brain from cerebral ischemia/reperfusion injury (Liu et al., 2016a). In another study, EA pretreatment (dense disperse wave; frequency, 2--15 Hz; intensity, 1 mA) was applied at the *Baihui* (GV20) acupoint in male C57BL6 mice with cerebral ischemia/reperfusion injury 30 min/day for 5 days. The results revealed that the Neurological Severity Score was significantly higher in the ischemia/reperfusion (I/R) group than in the sham group. Importantly, EA pretreatment markedly decreased the Neurological Severity Score. Moreover, the protein expression levels of mTOR and phosphorylated mTOR (p-mTOR) increased in the I/R group compared with the sham group, and EA pretreatment further promoted the expression of these proteins in the hippocampus (Zhou et al., 2016).

It has also reported that p53 plays a positive role in the activation of autophagy (White, 2016). EA pretreatment (dense disperse wave; frequency, 2--15 Hz; intensity, 1 mA) at the GV20 acupoint was applied to male Sprague-Dawley rats with cerebral ischemia/reperfusion injury 30 min/day, 5 days/week, for 2 weeks. The results were increased protein expression levels of phosphorylated p53 (p-p53), p53, and LC3-II in the I/R group compared with the sham group, while pretreatment with EA significantly attenuated these increases in (Li et al., 2018).

Electroacupuncture in vesicle nucleation {#sec2-2}
----------------------------------------

The nucleation of vesicles is mainly mediated by class-III PI3K, Beclin1, Atg1, Atg9, and p150, among which, Beclin1 plays a crucial role (Funderburk et al., 2010; Mei et al., 2016). In one study (Shu et al., 2016), after establishing a male Sprague-Dawley rat model of cerebral ischemia/reperfusion injury by middle cerebral artery occlusion surgery, EA treatment (frequency, 2--20 Hz) was applied continuously for 30 minutes, once/day to the *Shuigou* (GV26) acupoint at different times after reperfusion. The results showed that EA stimulation at 24 and 72 hours after reperfusion greatly decreased cerebral infarct volume. Additionally, the protein cortical expression levels of Beclin1 decreased in the EA group compared with the I/R group, and there was a statistically significant difference between the EA and I/R 24-hours groups. Similar results were also reported in other studies. One showed that pretreatment with EA at GV20 (frequency, 2--15 Hz; intensity, 1 mA) in male Sprague-Dawley rats 30 min/day for 5 days before middle cerebral artery occlusion remarkably down-regulated Beclin 1 protein expression levels (Wu et al., 2015).

However, another study showed the opposite result. After establishing a Sprague-Dawley rat model of cerebral ischemia/reperfusion injury by suture occlusion of the left middle cerebral artery, EA stimulation (dense disperse wave; frequency, 1--20 Hz; peak voltage, 6 V) at *Shenting* (GV24) and GV20 acupoints was administered 30 min/day for 7days beginning 2 hours after reperfusion. The results revealed that latency on a water-maze test markedly decreased in the EA group compared with the I/R group. Further, protein and mRNA expression levels of Beclin-1 in the hippocampus and left cerebral cortex markedly increased in the I/R group compared with the sham group, while treatment with EA for 10 days further up-regulated Beclin1 expression (Feng et al., 2018).

Another study reported that anti-apoptotic Bcl-2 family members---such as Bcl-2---interact with the Bcl-2-homology 3 motif of Beclin1 to suppress the formation of the Vps34-Beclin1 complex, thereby inhibiting the nucleation of vesicles (Kang et al., 2011). One study showed applied EA (dispersed wavelength; frequency, 1--20 Hz; intensity, 6 mA) at GV20 and GV24 acupoints 30 min/day for 14 days in Sprague-Dawley rats beginning 24 hours after middle cerebral artery-occlusion surgery. They found a reduction in the average escape latency over the 6-day testing period and up-regulation of Bcl-2 mRNA expression levels (Liu et al., 2015).

Electroacupuncture modulates the expansion and maturation of autophagosomes {#sec2-3}
---------------------------------------------------------------------------

A series of molecules have been reported to be involved in the expansion and maturation of autophagosomes, among which, LC3 plays a crucial role in promoting their formation (Huang and Liu, 2015). The carboxyl (C)-terminal amino acids of LC3 are cleaved by Atg4 to expose the glycine residue, transforming it into LC3-I, which is soluble. Soluble LC3 is converted to the membrane-bound form LC3-II *via* conjugation with phosphatidylethanolamine and the assistance of the E1-like enzyme Atg7 and the E2-like enzyme Atg3 (Huang et al., 2015a). LC3-II is attached to the surface of the vesicle membrane to promote the extension of the double-layer membrane, which is eventually sealed to form the mature autophagosome. Thus, this protein is an autophagosomal marker.

A middle cerebral artery-occlusion model was established in male Sprague-Dawley rats to induce cerebral ischemia for 2 hours followed by reperfusion. Continuous EA stimulation at LI11 and ST36 acupoints (dense disperse wave; frequency, 1--20 Hz; peak voltage, 6 V) was applied 30 min/day for 3 days to rats with cerebral ischemia/reperfusion injury. The results were that EA reduced the cerebral infarct volume that was induced by cerebral ischemia/reperfusion injury. In addition, a western blot assay showed that EA inhibited the conversion of LC3B-I to LC3B-II and greatly down-regulated the protein expression levels of Atg4 (He et al., 2015). Similar results were also reported in other studies. One study revealed that EA treatment at GV26 in Sprague-Dawley rats dramatically down-regulated the expression of LC3-II and the LC3-II/LC3-I ratio (Shu et al., 2016). Another study administered EA treatment at LI11 and ST36 acupoints (density wave; frequency, 1--20 Hz; peak voltage, 6 V) 30 min/day beginning 24 hours after reperfusion in Sprague-Dawley rats with cerebral ischemia/reperfusion injury. They found that EA treatment for 3 days significantly decreased the LC3B-II/LC3B-I ratio in the rats (Liu et al., 2016a). Additionally, pretreatment with EA at GV20 also reduced cerebral infarct volume and the LC3-II/LC3-I ratio in Sprague-Dawley rats with cerebral ischemia/reperfusion injury (Wu et al., 2015).

Electroacupuncture modulates how autophagosomes fuse with lysosomes {#sec2-4}
-------------------------------------------------------------------

Autophagolysosomes---which are formed when mature autophagosomes fuse with lysosomes---are considered one of the most accurate markers of autophagy. The structure and quantity of autophagosomes and autophagolysosomes can be observed by electron microscopy. Mature autophagosomes are double-membrane limited vacuoles containing undegraded cytoplasm such as ER membranes and mitochondria but no lysosomal proteins (Ylä-Anttila et al., 2009; Ma et al., 2012). Accumulation of autophagosomes indicates either the activation of autophagy or a blockage steps downstream of autophagy, such as inefficient fusion and decreased lysosomal degradation.

One study reported that in rats with cerebral ischemia/reperfusion injury, the numbers of lysosomes and autophagolysosomes increased in the striatum around ischemic areas, chromatins were edge-aggregated, and mitochondrial spines were disordered. EA stimulation applied to LI11 and ST36 for 3 days greatly reduced the numbers of lysosomes and autophagolysosomes, and also ameliorated the damaged mitochondria ultrastructure (Liu et al., 2016c). Another study reported that numerous autophagosomes and lysosomes that had engulfed cytoplasmic materials were observed in Sprague-Dawley rats with middle cerebral artery occlusion (ischemia for 2 hours followed by reperfusion for 12 hours), while quantitative analysis *via* electron microscopy images showed that EA pretreatment at GV20 remarkably reduced the numbers of autophagosomes (Wu et al., 2015). Furthermore, Liu et al. (2016a) also found that the numbers of autophagosomes, autolysosomes, and lysosomes markedly increased in Sprague-Dawley rats with cerebral ischemia/reperfusion injury, while EA stimulation at LI11 and ST36 for 3 days reversed this increase.

Electroacupuncture modulates the degradation of autophagolysosomes {#sec2-5}
------------------------------------------------------------------

p62---an adapter protein---plays a critical role in degradation (Komatsu and Ichimura, 2010). Serving as a bridge between ubiquitinated proteins and LC3, p62 binds with ubiquitinated proteins at the C-terminal and interacts with LC3-II at the N-terminal to form a complex that is finally degraded within autophagolysosomes (Long et al., 2017).

Li et al. (2016) reported that EA stimulation influenced this degradation. They first established a middle cerebral artery occlusion model in Sprague-Dawley rats in which they induced cerebral ischemia for 2 hours followed by reperfusion for 6, 24, or 72 hours. EA stimulation was applied to GV26 (continuous wave; frequency, 2 Hz; intensity, 1 mA) for 30 min/day before sacrifice. The results revealed that EA treatment ameliorated neurological deficits. In addition, the protein expression level of p62 was markedly lower 6 hours and 24 hours after reperfusion, but there was no significant decrease 72 hours after reperfusion. Treatment with EA 6 hours and 24 hours after reperfusion noticeably attenuated the decrease in p62 levels. No significant differences in p62 levels were found between the groups at 72 hours.

Electroacupuncture Modulates the Signaling Pathways that Control Autophagy {#sec1-5}
==========================================================================

An increasing number of studies have demonstrated that autophagy is involved in cerebral ischemia/reperfusion injury through a variety of signaling pathways (Guo, 2017; He et al., 2017; Yu et al., 2017). However, the modulation of autophagy-related signaling pathways by EA treatment has not yet been completely elucidated. Previous studies have indicated that EA treatment probably modulates autophagy *via* the PI3K-mTOR signaling pathway (He et al., 2015) (**[Figure 2](#F2){ref-type="fig"}**).

![Modulation of autophagy the signaling pathway by electroacupuncture (EA) for treating cerebral ischemia/reperfusion (CIR) injury.\
EA activates class-I phosphatidylinositol 3-kinase (PI3K) to promote the generation of phosphatidylinositol (3,4,5)-trisphosphate (PIP3), which can activate protein kinase B (AKT) through phosphorylating AKT at Thr308 and Ser473. AKT subsequently inhibits the tuberous sclerosis 1/2 (TSC1/2) complex, leading to the activation of Ras homolog enriched in brain (Rheb) and mammalian target of rapamycin (mTOR), and finally inhibiting autophagy. PIP2: Phosphatidylinositol (4,5)-bisphosphate.](NRR-14-954-g002){#F2}

The PI3K-mTOR signaling pathway is known to be a classical autophagy pathway. The PI3K family is classified into three subgroups: class-I, II, and III PI3K. Generally, class-I PI3K activates and participates in the conversion of phosphatidylinositol (4,5)-bisphosphate (PIP2) lipids to phosphatidylinositol (3,4,5)-trisphosphate (PIP3) (Hemmings and Restuccia, 2012). PIP3 serves as a second messenger to recruit proteins bearing PH domains. Among these proteins, protein kinase B (AKT) plays a pivotal role in class-I PI3K signaling networks. AKT binds to the PIP3-rich region on the plasma membrane, allowing 3-phosphoinositide-dependent protein kinase 1 (PDK1) to phosphorylate Thr308 and Ser473 in the "activation loop", leading to fully active AKT (Yu et al., 2015). TSC2 is directly phosphorylated by AKT, which destabilizes TSC2 and disrupts its interaction with TSC1, relieving the inhibition of Rheb, thus making mTOR activation possible and finally inhibiting the activation of autophagy (Inoki et al., 2002; Wataya-Kaneda, 2015).

In one study, EA was applied to LI11 and ST36 acupoints (dense disperse wave; frequency, 1--20 Hz; peak voltage, 6 V) for 30 min/day in Sprague-Dawley rats with cerebral ischemia/reperfusion injury. Expression levels of PI3K and mTOR proteins in cerebral cortex significantly decreased in the I/R group compared with the sham group, and EA treatment for 3 days markedly attenuated these decreases (He et al., 2015). In another study, EA pretreatment (frequency, 2--15 Hz; intensity, 1 mA) for 30 min/day was performed at GV20 in Sprague-Dawley rats with cerebral ischemia/reperfusion injury. The study results indicated that cerebral infarct volume and LC3-II protein expression levels in cerebral cortex were remarkably higher in the I/R group compared with the sham group. EA pretreatment for 5 days markedly reduced cerebral infarct volume and down-regulated LC3-II expression. Further analysis indicated that the protein expression levels of phosphorylated AKT (p-AKT) at Thr308 and phosphorylated mTOR (p-mTOR) were noticeably higher in the cortices of the I/R group than in the sham group. EA pretreatment further promoted the expression of p-AKT and p-mTOR (Wu et al., 2015).

Conclusion {#sec1-6}
==========

As a crucial pathological change in cerebral ischemia/reperfusion injury, autophagy plays a double-edged role. During the first few hours of reperfusion, autophagy helps maintain cell survival through clearing damaged organelles. However, excessive autophagy at later stages leads to autophagic cell death (Yan et al., 2011; Gao et al., 2012; Xia et al., 2013). Therefore, autophagy may be a potential therapeutic target for ischemic cerebrovascular diseases. EA, an important alternative therapy, can effectively reduce the risk of recurring ischemic cerebrovascular disease and disability. In recent years, results from animal experiments have demonstrated that EA exerts an influence on the whole process of autophagic flux by regulating the expression of autophagy-related markers such as the ULK1 complex, Beclin1, LC3 and p62. Other studies have indicated that EA treatment might regulate autophagy *via* the PI3K-AKT-mTOR signaling pathway, thereby playing a neuroprotective role in cerebral ischemia/reperfusion injury (**[Table 1](#T1){ref-type="table"}**).

###### 

Effect of acupuncture on autophagy in cerebral ischemia and reperfusion

  Acupoint     Method   Pre/post-treatment   Frequency       Intensity   Duration   Effects of acupuncture                                                                 References
  ------------ -------- -------------------- --------------- ----------- ---------- -------------------------------------------------------------------------------------- --------------------
  GV20GV24     EA       Post-treatment       1--20 Hz        --          30 min     Beclin1↑                                                                               Feng et al. (2018)
  GV20         EA       Pre-treatment        2--15 Hz        1 mA        30 min     LC3-II↓, LC3-II/LC3-I↓, p-p53 ↓, p53↑                                                  Li et al. (2018)
  GV20         EA       Pre -treatment       2--15 Hz        1 mA        30 min     LC3-C/LC3-I↓, Beclin1↓, autophagosomes↓                                                Wu et al. (2015)
  GV20         EA       Post-treatment       40--50 Hz       --          20 min     LC3↓, Beclin1↓, mTOR↑                                                                  Ting et al. (2017)
  GV4                                                                                                                                                                      
  ST36                                                                                                                                                                     
  LI11         EA       Post-treatment       1--20 Hz        0.2 mA      30 min     LC3-II/LC3-I↓, Beclin1↓, mTOR↑, ULK1↓, Atg13 ↓, autophagosomes↓, autophagolysosomes↓   Liu et al. (2016a)
  ST36                                                                                                                                                                     
  GV20         EA       Pre-treatment        2--15 Hz        1 mA        30 min     mTOR↑, p-mTOR↓                                                                         Zhou et al. (2016)
  GV26         EA       Post-treatment       2--20 Hz        --          30 min     LC3-II/LC3-I↓, Beclin1↓                                                                Shu et al. (2016)
  LI11         EA       Post-treatment       1--20 Hz        --          30 min     LC3-II/LC3-I↓, autophagolysosomes↓                                                     Liu et al. (2016c)
  ST36                                                                                                                                                                     
  GV24         EA       Post-treatment       1--20 Hz        --          30 min     Beclin1↓                                                                               Feng et al. (2016)
  GV20                                                                                                                                                                     
  LI11         EA       Post-treatment       1--20 Hz        --          30 min     LC3-II/LC3-I↓, Beclin1↓, PI3K↑, mTOR↑                                                  He et al. (2015)
  ST36                                                                                                                                                                     
  GV26         EA       Post-treatment       120 beats/min   1 mA        30 min     T6h/24h: P62↑                                                                          Li et al. (2016)
  T72h: P62↓                                                                                                                                                               
  GV20         EA       Pre-treatment        2--15 Hz        1 mA        30 min     LC3-II↓, LC3-II/LC3-I↓, autophagosomes↓, p-AKT↑, p-mTOR↑                               Wu et al. (2017)

↑: Up-regulation of protein expression; ↓: down-regulation of protein expression. GV20: *Baihui*; GV24: *Shenting*; GV4: *Mingmen*; GV26: *Shuigou*; LI11: *Quchi*; ST36: *Zusanli*; EA: electroacupuncture; LC3: microtubule associated protein-1 light chain 3; mTOR: mammalian target of rapamycin; ULK1: UNC-51-like kinase-1; Atg13: autophagy-related-gene13; PI3K: phosphatidylinositol 3-kinase; p-AKT: phosphorylated AKT; p-mTOR: phosphorylated mammalian target of rapamycin; p-p53: phosphorylated p53; min: minutes; T6, 24, 72h: reperfusion for 6, 24, 72 hourss.

This review suggests that the regulation of autophagy for EA treatment against cerebral ischemia/reperfusion injury depends on the timing of ischemia and reperfusion, as well as the EA parameters such as selected acupoints, current intensity, waveform, and duration. The duration of ischemia is generally 1.5 hours or 2 hours, and reperfusion usually occurs 6, 12, 24, or 72 hours afterward. Recent studies indicate that after cerebral ischemia for 2 hours, EA treatment within 2 hours of reperfusion may combat cerebral ischemia/reperfusion injury by promoting autophagy (Feng et al., 2016). However, EA treatment more than 24 hours after reperfusion might work against cerebral ischemia/reperfusion injury by suppressing autophagy (Liu et al., 2016b). Therefore, we propose that the timing of ischemia and reperfusion plays a key role in determining the mechanisms through which EA regulates autophagy.

EA is a form of acupuncture in which a small electric current is passed between pairs of acupuncture needles. It is characterized as being safe without toxic side effects and is being accepted by more and more countries and regions. However, the acupoints for EA treatment of cerebral ischemia/reperfusion injury are still controversial. The commonly selected acupoints are GV20, GV24, GV26, LI11, and ST36 (**[Figure 3](#F3){ref-type="fig"}**). Moreover, the effects on the nervous system and brain injury depend on how many acupoints are used; one or many. Therefore, to better understand the mechanisms through EA treatment regulates autophagy in cerebral ischemia/reperfusion injury, more attention should be paid to the selection of acupoints.

![Acupoints reported in literatures (He et al., 2015; Wu et al., 2015, 2017; Feng et al., 2016, 2018; Li et al., 2016, 2018; Liu et al., 2016a, c; Shu et al., 2016; Zhou et al., 2016) to which acupuncture was applied to treat cerebral ischemia/reperfusion injury.\
GV20: *Baihui*; GV24: *Shenting*; GV26: *Shuigou*; LI11: *Quchi*; ST36: *Zusanli*.](NRR-14-954-g003){#F3}

In summary, the mechanisms of regulating autophagy *via* EA treatment in cerebral ischemia/reperfusion injury needs to be further studied. Experiments on the role of autophagy in cerebral ischemia/reperfusion injury, the EA parameters, and selected acupoints will help provide the best EA therapy for modulating autophagy in the treatment of ischemic cerebrovascular diseases.
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